To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis

Published:2023-01-18 Issue:1 Volume:26 Page:139-148
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Montgomery Stephen Maxwell¹^ORCID,Green Luke¹,Karoui Hajer²^ORCID,Nicholas Richard²³^ORCID,Loh Jaclyn⁴^ORCID

Affiliation:

1. Costello Medical Consulting Ltd, Cambridge, UK

2. Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK

3. Department of Brain Sciences, Imperial College Healthcare NHS Trust, London, UK

4. Novartis Pharmaceuticals UK Ltd, London, UK

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2161746

Reference42 articles.

1. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis

2. Multiple Sclerosis Trust – How common is multiple sclerosis? 2022. https://mstrust.org.uk/a-z/how-common-multiple-sclerosis

3. Multiple Sclerosis Trust. Types of MS. Relapsing remitting MS (RRMS). 2022. https://www.mssociety.org.uk/about-ms/types-of-ms/relapsing-remitting-ms

4. Multiple sclerosis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study;Clinical Neurology and Neurosurgery;2024-05